ReviewExpert review of anti-infective therapy2014
Reverse genetics systems as tools for the development of novel therapies against filoviruses.
Review in Expert review of anti-infective therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The development and characterization of a stable Coxsackievirus A16 infectious clone with Nanoluc reporter gene.Frontiers in microbiology · 2022Article
- Article
- Therapeutic strategies to target the Ebola virus life cycle.Nature reviews. Microbiology · 2019Review
- Ebola virus VP35 has novel NTPase and helicase-like activities.Nucleic acids research · 2019Article
- The Natural Product Eugenol Is an Inhibitor of the Ebola Virus In Vitro.Pharmaceutical research · 2019Article
- Review
- Lifecycle modelling systems support inosine monophosphate dehydrogenase (IMPDH) as a pro-viral factor and antiviral target for New World arenaviruses.Antiviral research · 2018Article
- A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle.Genome medicine · 2018Article
- Post-exposure treatments for Ebola and Marburg virus infections.Nature reviews. Drug discovery · 2018Review
- Novel Stable Ebola Virus Minigenome Replicon Reveals Remarkable Stability of the Viral Genome.Journal of virology · 2017Article
- Characterization of the catalytic center of the Ebola virus L polymerase.PLoS neglected tropical diseases · 2017Article
- Immunobiology of Ebola and Lassa virus infections.Nature reviews. Immunology · 2017Review
- Article
- A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus.PLoS neglected tropical diseases · 2016Article
- Teicoplanin inhibits Ebola pseudovirus infection in cell culture.Antiviral research · 2016Article
- Modeling the lifecycle of Ebola virus under biosafety level 2 conditions with virus-like particles containing tetracistronic minigenomes.Journal of visualized experiments : JoVE · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Filoviruses cause severe hemorrhagic fevers with case fatality rates of up to 90%, for which no antivirals are currently available. Their categorization as biosafety level 4 agents restricts work with infectious viruses to a few maximum containment laboratories worldwide, which constitutes a significant obstacle for the development of countermeasures. Reverse genetics facilitates the generation of recombinant filoviruses, including reporter-expressing viruses, which have been increasingly used for drug screening and development in recent years. Further, reverse-genetics based lifecycle modeling systems allow modeling of the filovirus lifecycle without the need for a maximum containment laboratory and have recently been optimized for use in high-throughput assays. The availability of these reverse genetics-based tools will significantly improve our ability to find novel antivirals against filoviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.